About us Contacts Drug interactions: 390 212
Drug search by name

Dilantin Infatabs and Vfend

Determining the interaction of Dilantin Infatabs and Vfend and the possibility of their joint administration.

Check result:
Dilantin Infatabs <> Vfend
Relevance: 04.07.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using voriconazole together with phenytoin can alter the blood levels and effects of both medications. Specifically, voriconazole levels may decrease, which may make the medication less effective in treating your fungal infection. At the same time, phenytoin levels may increase, and you may experience more frequent and/or severe side effects. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your conditions worsen or you develop signs and symptoms that may indicate excessive blood levels of phenytoin such as nausea, vomiting, tremor, incoordination, slurred speech, and/or visual disturbances. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

ADJUST DOSE: Coadministration of phenytoin and voriconazole may significantly reduce the plasma concentrations of voriconazole and increase the plasma concentrations of phenytoin. The mechanism involves phenytoin induction of voriconazole metabolism via CYP450 2C19, 2C9 and 3A4, and voriconazole inhibition of phenytoin metabolism via CYP450 2C9 and 2C19. In healthy male subjects, administration of voriconazole (200 mg orally every 12 hours) with phenytoin (300 mg once daily) for 14 days decreased the mean steady-state voriconazole peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 49% and 69%, respectively, compared to administration with placebo. Doubling the dosage of voriconazole and giving it with the same dosage of phenytoin for 7 days resulted in steady-state voriconazole Cmax and AUC that were comparable to those observed when voriconazole was administered alone at 200 mg twice daily or with placebo. However, in a case report of a 27-year-old woman receiving phenytoin 400 mg/day and voriconazole 400 mg orally twice daily for suspected central nervous system Aspergillus infection, the patient developed breakthrough oral candidiasis after six weeks of cotreatment. A dosage increase of voriconazole to 400 mg orally three times a day was required, whereupon the patient's condition stabilized and no toxicity was observed. Conversely, administration of phenytoin (300 mg once daily) with voriconazole (400 mg twice daily) for 10 days increased the mean Cmax and AUC of phenytoin by approximately 67% and 81%, respectively, compared to administration with placebo. The increases may be expected to be as high as two times the values observed when phenytoin is given without voriconazole. The combination was generally well tolerated in study patients, with most adverse effects classified as either mild or moderate.

MANAGEMENT: During concomitant therapy with phenytoin, the manufacturer recommends that maintenance dosage of voriconazole be increased from 4 mg/kg to 5 mg/kg every 12 hours when given intravenously, and from 200 mg to 400 mg every 12 hours when given orally (or from 100 mg to 200 mg every 12 hours in patients who weigh less than 40 kg). Frequent monitoring of plasma phenytoin levels and phenytoin-related adverse effects is recommended. Patients should be advised to contact their doctor if they experience symptoms of phenytoin toxicity such as nausea, vomiting, tremor, ataxia, lethargy, slurred speech, visual disturbances, and/or changes in mental status. Some experts also recommend monitoring plasma voriconazole levels, particularly in critically ill patients. Inadequate levels of voriconazole in the presence of phenytoin have been reported rarely, despite increasing voriconazole dosage as recommended. Additionally, measuring voriconazole levels following withdrawal of phenytoin can help to determine when to readjust voriconazole dosage.

References
  • Alffenaar JW, van der Elst KC, Uges DR, Kosterink JG, Daenen SM "Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage." Br J Clin Pharmacol 68 (2009): 462-3
  • Gerzenshtein L, Patel SM, Scarsi KK, Postelnick MJ, Flaherty JP "Breakthrough Candida infections in patients receiving voriconazole." Ann Pharmacother 39 (2005): 1342-5
  • "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.
  • Spriet I, Meersseman P, Meersseman W, de Hoon J, Willems L "Increasing the dose of voriconazole compensates for enzyme induction by phenytoin." Br J Clin Pharmacol 69 (2010): 701-2
  • Ullmann AJ "Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole." Curr Med Res Opin 19 (2003): 263-71
  • Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A "Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration." Br J Clin Pharmacol 56 Suppl 1 (2003): 37-44
Dilantin Infatabs

Generic Name: phenytoin

Brand name: Dilantin, Phenytek, Dilantin Infatabs, Phenytoin Sodium, Prompt

Synonyms: Dilantin

Vfend

Generic Name: voriconazole

Brand name: Vfend, Vfend

Synonyms: Vfend Injection

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction